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Abstract
Background—Population-based data on melanoma survival are important for understanding the 
impact of demographic and clinical factors on prognosis.
Objective—We describe melanoma survival by age, sex, race/ethnicity, stage, depth, histology, 
and site.
Methods—Using Surveillance, Epidemiology, and End Results data, we calculated unadjusted 
cause-specific survival up to 10 years from diagnosis for 68,495 first primary cases of melanoma 
diagnosed from 1992 to 2005. Cox multivariate analysis was performed for 5-year survival. Data 
from 1992 to 2001 were divided into 3 time periods to compare stage distribution and differences 
in stage-specific 5-year survival over time.
Results—Melanomas that had metastasized (distant stage) or were thicker than 4.00 mm had a 
poor prognosis (5-year survival: 15.7% and 56.6%). The 5-year survival for men was 86.8% and 
for persons given the diagnosis at age 65 years or older was 83.2%, varying by stage at diagnosis. 
Scalp/neck melanoma had lower 5-year survival (82.6%) than other anatomic sites; unspecified/
overlapping lesions had the least favorable prognosis (41.5%). Nodular and acral lentiginous 
melanomas had the poorest 5-year survival among histologic subtypes (69.4% and 81.2%, 
respectively). Survival differences by race/ethnicity were observed in the unadjusted survival, but 
nonsignificant in the multivariate analysis. Overall 5-year melanoma survival increased from 
87.7% to 90.1% for melanomas diagnosed in 1992 through 1995 compared with 1999 through 
2001, and this change was not clearly associated with a shift toward localized diagnosis.
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Limitations—Prognostic factors included in revised melanoma staging guidelines were not 
available for all study years and were not examined.
Conclusions—Poorer survival from melanoma was observed among those given the diagnosis at 
late stage and older age. Improvements in survival over time have been minimal. Although newly 
available therapies may impact survival, prevention and early detection are relevant to melanoma-
specific survival.
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More than 50,000 people are given the diagnosis of melanoma in the United States every 
year, according to the US Cancer Statistics report.1 In addition to the stage at diagnosis, 
previous studies have shown other factors are related to prognosis such as histology, location 
on body, and socioeconomic status (SES).2-5 In this study, we used the data from population-
based cancer registries to describe melanoma survival by demographic and clinical factors.
METHODS
We analyzed data from the 13 registries that participate in the National Cancer Institute 
Surveillance, Epidemiology, and End Results (SEER) program (Atlanta, GA; Connecticut; 
Detroit, MI; Hawaii; Iowa; New Mexico; San Francisco-Oakland, CA; Seattle-Puget Sound, 
WA; Utah; Los Angeles, CA; San Jose-Monterey, CA; rural Georgia; and the Alaska Native 
Tumor Registry). The coverage of these SEER-13 registries represented 14% of the US 
population and met uniform data standards for cancer registration.6
We identified 133,386 cases of melanoma diagnosed between 1992 and 2005 at age 15 years 
or older and reported to a SEER-13 registry. We excluded 37,160 in situ melanoma cases 
(27.9%); 26,282 melanoma cases that were not the first cancer diagnosed (19.7%); 145 cases 
found by death certificate only or autopsy; 275 cases not microscopically confirmed; 318 
cases with an unknown cause of death; 88 patients with unknown age; and 623 patients who 
had no survival time. Our final study population included 68,495 first primary invasive 
melanoma cases diagnosed in years 1992 to 2005 and followed up through 2006 to ensure at 
least 12 months of complete follow-up. Melanoma cases were identified by International 
Classification of Diseases for Oncology, Third Edition morphology codes (C440-C449)7 and 
categorized by histologic subtype as superficial spreading, lentigo maligna, acral 
lentiginous, nodular, not otherwise specified, and other.8 We chose not to collapse the 
histologic category “not otherwise specified” with “other” because the survival patterns for 
these two subtypes were different. A revised staging system for melanoma was introduced in 
the sixth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging 
Manual and implemented into cancer registries in 2003.9 To ensure consistency in staging 
across all study years, we used SEER historic stage, which provides consistent definitions 
over time (as opposed to AJCC staging, which is more commonly used in the clinical 
settings).10 SEER historic stages were localized (confined to primary site), regional (spread 
to regional lymph nodes), distant (cancer had metastasized), and unknown (unstaged). Depth 
of melanoma was classified as less than or equal to 1 mm, 1.01 to 2.00 mm, 2.01 to 4.00 
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mm, and greater than 4.00 mm. Anatomic sites were classified as face/ears (C440-C443), 
scalp and neck (C444), trunk (C445), extremities (C446-447), and not otherwise specified/
overlapping codes (C448-C449).7 Scalp and neck melanomas have been shown to have 
poorer survival than melanomas on the face, ear, and other anatomic sites,3 thus we analyzed 
them separately. Information on race and ethnicity was obtained from medical records by 
tumor registrars who reported melanoma to the SEER program.6 Identification of cases 
having Hispanic ethnicity was enhanced with the North American Association of Central 
Cancer Registries Hispanic Identification Algorithm.11 The availability and quality of 
variables on receipt of surgery, sentinel lymph node biopsy (SLNB), and radiation were 
limited, especially in the earlier years, and therefore not included in this analysis.
Analysis
Our main outcome of interest was survival time after a diagnosis of melanoma as the 
primary cancer. The cause of death information was from death certificates. We present 
cause-specific survival (eg, melanoma-specific survival [MSS]). For the unadjusted analyses, 
we used the Kaplan-Meier method to calculate MSS by gender, age at diagnosis, race, 
Hispanic ethnicity, stage and depth at diagnosis, anatomic site, and histologic subtype. To 
examine temporal trends in survival, we stratified cases into 3 time periods (1992-1995, 
1996-1998, and 1999-2001). For this analysis of survival time by time period and stage, we 
excluded cases diagnosed after 2001 to have a full 5 years of follow-up. We used the Z-test 
to examine any differences in 5-year survival between the earliest and most recent time 
period and χ2 to test for any significant change in the proportion of cases diagnosed at the 
local, regional, distant, and unknown stage (eg, stage distribution).
We explored whether survival differences can be explained by sociodemographic and 
clinical characteristics by performing a multivariate analysis for MSS using Cox regression 
modeling. Because of missing information on race/ethnicity, stage at diagnosis, and depth, 
this multivariate analysis was based on 56,886 study cases. We restricted the follow-up time 
in the Cox model to a 5-year follow-up period. We assessed the Cox proportional hazards 
assumption for each covariate by graphical examination of the log of the negative log 
survival curves versus time and by the Schoenfeld residual correlation test. Variables for 
histologic subtype and anatomic site were both found to violate the Cox proportional 
hazards assumption. Thus, the final Cox model was stratified on histologic subtype and 
anatomic site and included sex, age at diagnosis, race/ethnicity, stage at diagnosis, and 
depth.12,13 Hazard ratios (HR) and corresponding 95% confidence intervals (CI) were 
estimated to determine statistical significance. All the analyses were performed using 
SEER*Stat, Version 6.6 (IMS Inc, Silver Springs, MD) and SAS, Version 9.2 (SAS Institute, 
Cary, NC).
RESULTS
This study included 68,495 invasive melanoma cases diagnosed from 1992 to 2005 in the 13 
SEER registries. Table I shows the distribution of melanoma incidence by demographic and 
clinical characteristics and 1-, 5-, and 10-year MSS. Figs 1 and 2 show Kaplan-Meier cause-
specific survival curves. Overall, the 1-year MSS was 96.9%. The 5- and 10-year MSS were 
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89.2% and 85.1%. The MSS for males and females was 96.3% and 97.7% at year 1 and 
86.8% and 92.0% at year 5, respectively. Age at diagnosis impacted survival. Men and 
women given the diagnosis at age 65 years and older had a lower 5-year survival than those 
at age 40 to 64 years and 15-39 years (83.2% vs 90.6% and 94.4%) (Table I). As time from 
diagnosis increased, so did the differences between the MSS of the oldest and younger age 
groups (Fig 1). The 10-year MSS was 77.0% for cases diagnosed at age 65 years, which was 
lower than 86.7% and 91.9% for the two younger age categories. We analyzed MSS by age 
and stage at diagnosis and found that the difference between the youngest (15-39 years) and 
oldest (≥ 65 years) age group was more pronounced for regional stage melanomas (73.5% vs 
58.2%) than localized stage (98.0% vs 92.3%) (data not shown). Whites accounted for 
95.2% of the study population and had a favorable prognosis at diagnosis (96.9% 1-year and 
89.0% 5-year MSS) compared with blacks (72.2% 5-year MSS) and Asian/Pacific Islanders 
(79.2% 5-year MSS). Ethnicity also impacted survival. Non-Hispanic whites had a higher 5-
year survival than Hispanic whites (89.2% vs 82.9%). Melanoma diagnosed at the localized 
stage had a 99.7% 1-year MSS, but despite early detection there were still deaths attributable 
to melanoma at the localized stage (10-year MSS 92.1%). In contrast, diagnoses at a distant 
stage had poor prognoses (1-year MSS 41.3%). For regional and distant stage melanomas, 
MSS decreased rapidly from year 1 to year 3 and then stabilized from year 5 to year 10 (Fig 
2, A). Given that depth of melanoma is a major determinant of stage of diagnosis, as 
expected, lesions less than 1.00 mm had a 5-year MSS of 97.4% whereas the 5-year MSS for 
lesions that were 2.01 to 4.00 mm was 72.7% and, for lesions with a depth greater than 4.00 
mm, MSS was 56.6% (Fig 2, B). Two histologic subtypes with favorable prognosis were 
superficial spreading and lentigo maligna. For both, MSS exceeded 99% at year 1, 95% 
MSS at year 5, and remain over 92% at year 10 (Fig 2, C). In contrast, the 1-, 5-, and 10-
year MSS of nodular and acral lentiginous melanoma were substantially different. Survival 
by anatomic site was similar for melanoma diagnosed on the face/ears, trunk, and 
extremities (5-year MSS 90.2%, 91.2%, 92.5%) but less for melanoma on the scalp and neck 
(5-year MSS 82.6%, 10-year MSS 75.6%) and unspecified and overlapping lesions (5-year 
MSS 41.5%) (Fig 2, D).
A modest increase in the overall 5-year cause-specific survival for melanoma was observed 
between the time periods of 1992 to 1995 (87.7% [95% CI 87.1-88.2]) and 1999 to 2001 
(90.1% [95% CI 89.6-90.5]) (Table II). Comparing these two time periods, there was a 
decrease in the proportion of unstaged cases from 5.9% to 2.1% of overall cases (P < .001). 
Among the cases that were staged, compared with cases diagnosed in 1992 through 1995, 
the proportion of localized cases decreased in the most recent time period of 1999 to 2001, 
whereas the proportion of cases diagnosed at the regional stage increased, and the change in 
proportion diagnosed at the distant stage was very small (P<.001 for overall change in 
distribution). Patients given the diagnosis at the localized and regional stages from 1999 to 
2001 had significantly increased 5-year survival compared with patients given the diagnosis 
of same-stage cancer from 1992 to 1995. For melanoma diagnosed at a distant stage, there 
was a slight, but not significant, increase in 5-year MSS from the earliest to latest diagnostic 
time period.
After controlling for demographic and clinical factors through multivariate analysis, we 
found sex and age remained significantly associated with 5-year survival (Table III). The 
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risk of death for females was lower than for males (HR 0.76 [0.71-0.81]), as were the two 
younger age groupings (HR 0.66 [0.62-0.71] for ages 40-64 years and HR 0.49 [0.44-0.54] 
for ages 15-39 years) compared with those older than 65 years. Racial/ethnic differences in 
survival were attenuated in our multivariate model. The risk of melanoma death for blacks 
was over one-third higher than for non-Hispanic whites, but did not reach statistical 
significance (HR 1.33 [0.98-1.78]). The survival differences by Hispanic ethnicity (limited 
to cases of white race) also lost significance in the multivariate analysis (HR 1.06 
[0.92-1.24]). We found the stage at diagnosis and depth of melanoma to be important factors 
related to 5-year survival.
DISCUSSION
Our study results are consistent with earlier reports that stage at diagnosis and depth are 
significant factors related to MSS.9 Although depth is one factor that determines stage, the 
correlation between them was modest (21%), therefore, we kept both depth and stage in the 
model. Sex and age also remained significant prognostic factors in the adjusted analysis, 
with worse survival for men and those who were elderly at diagnosis. The difference in 
survival by age may be related to comorbidities, which could not be directly accounted using 
SEER data. Although we observed survival differences by race and ethnicity (for whites) in 
the unadjusted analysis, the association of race and ethnicity with survival was attenuated in 
the multivariate analysis.
Gender difference in melanoma survival have been reported in other studies.9,14-16 Although 
this observation is not well understood, previously published findings have suggested that 
older patients are given the diagnosis at later stages as a result of less screening; men are 
given the diagnosis of more nodular melanoma, which has a poorer prognosis; and that 
women undergo more screening and have melanomas in more favorable anatomic 
locations.10,15,17,18 Our multivariate analysis results showed that even adjusting for stage, 
the risk of death from melanoma was still higher for men than for women. Regarding race, 
the adjusted risk of death for blacks was higher than for non-Hispanic whites, but not 
statistically significant. This observation supports that there are racial differences in sex, age, 
and clinical factors of melanoma at diagnosis, which in turn impact survival. Previous 
studies have shown that blacks are disproportionately affected by acral lentiginous 
melanoma, a histologic subtype with worse survival than overall melanoma, likely because 
of acral lentiginous melanoma being diagnosed at later stages with thicker lesions.2,19 After 
accounting for stage, depth, and histologic subtype, we found survival differences for blacks 
compared with whites were less than in previously published work by Zell et al.5 Two major 
differences, however, were that the analysis of Zell et al5 used only California Cancer 
Registry data with 127 cases of melanoma among blacks, whereas our study used national 
SEER-13 data that included over twice the number of blacks; and, unlike the analysis of Zell 
et al,5 we did not adjust for SES and treatment. SES has been related to melanoma survival 
with increased survival for nonwhites and elderly persons with higher SES.4,5
We observed small improvements in survival at the localized and regional stage. A factor 
that could explain these observations and may have contributed to an increase in survival at 
these earlier stages is the adoption of SLNB around the year 2000, a technique that more 
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precisely identifies potentially affected lymph nodes.20 Using SLNB, some melanoma cases 
that may have been classified as localized are identified as regional because of the increased 
specificity of the diagnostic workup. As a result of this upstaging, the survival at the regional 
disease improves because of the addition of cases that would have otherwise been classified 
as localized, and survival at the localized stage also improves because of the identification 
and classification of more disseminated disease as regional stage.9,21 The impact of SLNB 
on overall survival is a topic of much debate in the current literature because the early 
removal of lymph nodes with micrometastatic disease has not been shown to improve overall 
survival, and there have been no randomized trials that have shown that early surgical 
removal of affected nodes improves overall survival compared with delaying removal of 
nodes until they are clinically palpable.22,23
We showed a small improvement in overall 5-year survival from the early 1990s to the 
period around the year 2000. During this time we found that more cases were being staged; 
however, we did not observe a dramatic shift toward melanoma being diagnosed at earlier 
stages as might be expected from increased screening for melanoma. In fact, among the 
melanoma cases that were staged, from the earliest to most recent time period, the 
percentage of all melanomas diagnosed at the localized stage decreased and the percentage 
of all melanomas diagnosed at the regional stage increased. Jemal et al24 showed that the 
incidence rates from 1992 to 2006 increased for all tumor depths, but did not take into 
account nodal involvement, metastasis, or other criteria that determine stage. Further 
exploration of how the revised staging systems impact the relative percentages of melanoma 
diagnosed at the localized versus regional stage warrants further study.
Our cause-specific analysis focused on melanoma as the underlying cause of death and did 
not include death from all other causes. The validity of MSS depends on the quality of 
recorded cause of death.21 Understanding this, we believed that using MSS was justified for 
our study because of the high quality of SEER data, and because ascertaining death from 
melanoma is not as challenging as other diseases as a result of ease of obtaining diagnosis 
through biopsy, and because of the tendency of disseminated disease to metastasize and be 
detected. Another approach we could have used is “relative survival,” which compares the 
observed survival of those given the diagnosis of melanoma with a comparable population 
without melanoma, thus bypassing the need for cause for death because of the focus on 
excess mortality among those with melanoma.21 We chose not to show relative survival 
because our preliminary analyses using both cause-specific and relative survival were similar 
(data not shown) and because there were no life tables available for racial and ethnic groups 
besides black and white. “Period survival” is an approach that captures improvements in 
survival to provide better estimates of long-term survival for more recently diagnosed 
cancer.
25
 Given the lack of significant progress in survival shown in our study (Table II), 
using period survival was unnecessary. A more recent, relevant approach is “conditional 
survival,” which conditions survival upon living to a certain time point, and has been applied 
to melanoma by Rueth et al26 to show that 8 years after surgical treatment from melanoma, 
the survival for high-risk melanoma is similar to low-risk disease.
Strengths of this study were the use of population-based, high-quality SEER data and the 
large number of melanoma cases, including cases among those who were black or Hispanic. 
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A limitation is that we were unable to use the complete US Cancer Statistics data set (SEER 
combined with National Program of Cancer Registries data)1 because the survival data are 
not consistently available from all National Program of Cancer Registries. Other limitations 
include the use of the North American Association of Central Cancer Registries Hispanic 
Identification Algorithm, which may misclassify Hispanic ethnicity because of the reliance 
of surname and other demographic variables rather than self-report.11 We did not account for 
all factors known to impact survival including treatment, prognostic factors in the revised 
staging system (nodal involvement, metastasis, and, more recently, mitoses, ulceration, and 
serum lactate dehydrogenase), SES, and physician specialty or availability as these data are 
not available in population-based registries.4,5,14,27,28 Also, we examined survival after 
diagnosis of the “first and primary” melanoma but did not limit cases to “first and only” 
melanoma. Thus, our data include people who may have had subsequent cancers, melanoma 
or otherwise, after a primary diagnosis of melanoma. It is important to be aware that certain 
medical conditions, such as atypical mole (dysplastic nevi) syndrome or 
immunosuppression, may predispose one to multiple diagnoses of melanoma and may 
impact survival.29-35
The contrast in melanoma survival by stage at diagnosis offers a compelling reason to 
support early detection and to support primary prevention through sun protection and 
avoidance of harmful ultraviolet light; these prevention efforts should be emphasized. 
Although, routine screening for early detection of lesions is not currently recommended by 
the US Preventive Services Task Force and Cancer Council Australia,36-38 early detection 
through screening should be considered for persons at risk for melanoma. Previous studies 
have found such screening program to be cost-effective, even if screening is not currently 
recommended. For instance, Freedberg et al39 used data from the US population and 
estimated a cost-effectiveness ratio of $29,170 per year of life saved for a one-time screening 
of self-selected patients at high-risk with a mean age of 48 years. Further, a study from 
Australia estimated a cost-effectiveness of annual melanoma screening in Australians aged 
50 years or older to be Aust. $12,137 and Aust. $20,877 (US$12,318 and US$21,188) for 
men and women, respectively.40
In conclusion, our study found minimal progress in survival from 1992 to 2005. The 
relevance of new therapies such as interferon alfa-2b and, more recently, immunotherapy 
(eg, ipilimumab) on prognosis will be determined in future studies.20,41 Until then, efforts to 
reduce melanoma deaths must continue through prevention, screening of persons at high 
risk, and elimination of disparities that lead to late diagnosis.
Abbreviations used
AJCC American Joint Committee on Cancer
CI confidence interval
HR hazard ratio
MSS melanoma-specific survival
SEER Surveillance, Epidemiology, and End Results
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SES socioeconomic status
SLNB sentinel lymph node biopsy
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CAPSULE SUMMARY
• Cancer registry data were used to calculate cause-specific survival up to 10 years 
from diagnosis for 68,495 first primary cases of melanoma diagnosed from 1992 
to 2005.
• Poorer survival from melanoma was observed among those given the diagnosis 
at late stage and older age.
• Improvements in survival over time have been minimal.
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Fig 1. 
Unadjusted Kaplan-Meier melanoma-specific survival curve by age at diagnosis, 
Surveillance, Epidemiology, and End Results-13, 1992 to 2005.
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Fig 2. 
Unadjusted Kaplan-Meier melanoma-specific survival curves by stage (A), depth (B), 
histology (C), and anatomic site (D), Surveillance, Epidemiology, and End Results-13, 1992 
to 2005. NOS, Not otherwise specified.
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Table I
Demographic and clinical characteristics of patients with invasive melanoma, Surveillance, Epidemiology, and 
End Results-13, 1992 to 2005
Melanoma-specific survival, %
Characteristic No. Percentage 1-y 5-y 10-y
Overall 68,495 96.9 89.2 85.1
Sociodemographic
        Sex
        Male 37,626 54.9 96.3 86.8 82.0
        Female 30,869 45.1 97.7 92.0 88.8
        Age at diagnosis, y
        15-39 13,383 19.5 98.6 94.4 91.9
        40-64 33,526 48.9 97.4 90.6 86.7
        ≥ 65 21,586 31.5 95.1 83.2 77.0
        Race/ethnicity*
        White 65,174 95.2 96.9 89.0 84.8
            White, non-Hispanic 63,140 92.2 96.9 89.2 85.0
            White, Hispanic 2034 3.0 95.1 82.9 79.0
        Black 318 0.5 89.5 72.2 68.2
        Asian/Pacific Islander 593 0.9 94.4 79.2 71.7
        American Indian/Alaskan Native 124 0.2 93.5 79.5 74.6
        Other/unknown 2286 3.3 99.8 99.2 98.0
        Hispanic 2104 3.1 95.3 83.3 79.5
Clinical
        Stage at diagnosis
        Localized 56,504 82.5 99.7 95.6 92.1
        Regional 7365 10.8 93.6 63.7 54.3
        Distant 2253 3.3 41.3 15.7 12.8
        Unstaged 2373 3.5 93.4 80.3 74.2
        Depth, mm
        No mass/tumor found 483 0.7 57.4 34.5 26.4
        0.01-1.00 40,935 59.8 99.6 97.4 95.2
        1.01-2.00 9520 13.9 98.7 88.4 81.2
        2.01-4.00 5190 7.6 96.5 72.7 62.1
        >4.00 2955 4.3 91.1 56.6 46.6
        Unknown 9412 13.7 87.4 75.4 71.2
        Histologic subtype
        Superficial spreading 26,054 38.0 99.5 95.8 92.6
        Lentigo maligna 4297 6.3 99.7 96.3 92.4
        Acral lentiginous 785 1.1 97.7 81.2 67.9
        Nodular 4998 7.3 94.3 69.4 60.8
        NOS 29,445 43.0 94.7 86.2 82.2
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Melanoma-specific survival, %
Characteristic No. Percentage 1-y 5-y 10-y
        Others 2916 4.3 96.2 83.4 78.1
        Anatomic site
        Face/ears 8153 11.9 98.4 90.2 85.5
        Scalp/neck 4328 6.3 96.6 82.6 75.6
        Trunk 23,293 34.0 98.3 91.2 87.1
        Extremities 29,990 43.8 98.7 92.5 88.8
            Upper limb/shoulder 16,229 23.7 98.7 93.0 89.5
            Lower limb/hip 13,761 20.1 98.6 91.8 88.0
        NOS/overlapping 2731 4.0 61.7 41.5 38.2
NOS, not otherwise specified.
*
Hispanics were not mutually exclusive from race. Whites included both non-Hispanic whites and Hispanic whites.
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Table II
Overall melanoma-specific 5-year survival by specified time periods, Surveillance, Epidemiology, and End 
Results-13, 1992 to 2005
Period I Period II Period III
1992-1995 1996-1998 1999-2001
N (%) 5-y Survival, % (95% 
CI)
N (%) 5-y Survival, % (95% 
CI)
N (%) 5-y Survival, % (95% 
CI)
Overall 16,262 87.7 (87.1-88.2) 14,286 89.1 (88.5-89.6) 15,604 90.1 (89.6-90.5)
    Staged 15,304 (94.1) 88.1 (87.5-88.6) 13,647 (95.5) 88.1 (87.5-88.6) 15,272 (97.9) 90.3 (89.8-90.7)
    Unstaged 958 (5.9) 80.9 (78.2-83.3) 639 (4.5) 80.0 (76.6-83.0) 332 (2.1) 79.6 (74.6-83.7)
Staged
    Localized 13,223 (86.4) 94.3 (93.8-94.6) 11,726 (85.9) 95.6 (95.2-96.0) 12,922 (84.6) 96.4 (96.1-96.7)
    Regional 1518 (9.9) 59.4 (56.8-62.0) 1468 (10.8) 61.3 (56.8-63.8) 1869 (12.2) 65.5 (63.2-67.7)
    Distant 563 (3.7) 14.0 (11.1-17.2) 453 (3.3) 16.4 (13.0-20.2) 481 (3.2) 16.6 (13.0-20.2)
Cases diagnosed after 2001 were excluded to have a full 5 years of follow-up. Percentages may not add to 100 because of rounding.
CI, Confidence interval.
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Table III
Cox multivariate analysis of 5-year survival for malignant melanoma, Surveillance, Epidemiology, and End 
Results-13, 1992 to 2005
Characteristic Hazard ratio* (95% CI)
Sex
    Male Ref.
    Female 0.76 (0.71-0.81)
Age at diagnosis, y
    ≥ 65 Ref.
    40-64 0.66 (0.62-0.71)
    15-39 0.49 (0.44-0.54)
Race/ethnicity
    White
        Non-Hispanic Ref.
        Hispanic 1.06 (0.92-1.24)
    Black 1.33 (0.98-1.78)
    Asian Pacific Islander/American 0.98 (0.76-1.25)
        Indian Alaskan Native
Stage at diagnosis†
    Localized Ref.
    Regional 3.62 (3.35-3.91)
    Distant 18.66 (16.54-21.06)
Depth, mm
    ≤ 1 Ref.
    1.01-2.0 2.89 (2.62-3.18)
    2.01-4.0 4.69 (4.24-5.02)
    >4.0 5.71 (5.10-6.39)
    No tumor found 3.03 (1.98-4.64)
CI, Confidence interval.
*Survival estimates are from Cox proportional hazards model accounting for histologic subtype, anatomic site, sex, age at diagnosis, race/ethnicity, 
stage at diagnosis, and depth.
†Surveillance, Epidemiology, and End Results (SEER) historic stage based on SEER summary stage 2000.
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